Dartmouth researcher Jack Hoopes has demonstrated that magnetic nanoparticle hyperthermia could be a possible treatment for breast cancer, as he presented in a new preclinical study at the American Association for Cancer Research annual meeting in San Diego.
A harmful gene mutation that increases a woman's risk of developing breast and ovarian cancer may also play a role in brain development, according to new findings by scientists at the Salk Institute for Biological Studies.
In the first detailed glimpse of palbociclib's impact on overall survival--a key feature to the future prospects of this flagship program--the therapy has failed to demonstrate a statistically significant improvement in extending patients' lives after an initial assessment.
Oncology biotech Tesaro will use a cancer test developed by Myriad Genetics to look for tumor types that may respond to PARP inhibitors like niraparib, a Phase III candidate in ovarian cancer and breast cancer, in-licensed from Merck in 2012.
In a courtroom development that does not bode well for Myriad Genetics' efforts to protect the BRCA breast cancer diagnostic technology it pioneered, a U.S. District judge in Utah dismissed the company's motion for a preliminary injunction to stop Ambry Genetics from selling its own version of the BRCA test.
A University of Rhode Island researcher won a National Institutes of Health grant of $1.3 million to further study the use of cancer-targeting copper sulfide nanoparticles for breast cancer.
NanoString Technologies has big plans going forward, and it's now got some extra funding to make those happen. The company has priced its follow-on offering at $55 million, which should give it a boost as it looks to follow up on last quarter's explosive growth.
To make drug delivery structures of a particular size and shape, researchers have developed gold nanoparticle building blocks that can be "glued" together with bits of DNA. This could have particular importance in delivering drugs to treat breast cancer.
Royal Philips on Thursday announced it is the first medical device company to win 510(k) clearance from the FDA for an application to measure breast density as part of routine mammograms. Women with dense breasts--i.e., less fatty tissue--may be at much higher risk of breast cancer.
African-American women who have high levels of a particular protein may be at risk for more aggressive breast cancer and poorer outcomes, according to new research from a Georgia State University study.